Chardan Capital Reaffirms Buy Rating for Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital’s target price suggests a potential upside of 361.54% from the company’s current price.

Separately, Laidlaw began coverage on shares of Senti Biosciences in a report on Friday, June 6th. They issued a “buy” rating and a $5.00 target price for the company.

Senti Biosciences Trading Down 9.1%

Shares of SNTI opened at $2.60 on Thursday. The firm has a market cap of $67.81 million, a PE ratio of -0.17 and a beta of 2.23. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The firm has a fifty day simple moving average of $3.37 and a two-hundred day simple moving average of $3.84.

Senti Biosciences (NASDAQ:SNTI) last announced its earnings results on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.85). The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.30 million. As a group, research analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences during the 4th quarter worth approximately $47,000. Renaissance Technologies LLC purchased a new position in shares of Senti Biosciences in the fourth quarter valued at $181,000. Heights Capital Management Inc. purchased a new position in shares of Senti Biosciences during the 1st quarter valued at approximately $2,520,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Senti Biosciences in the 1st quarter worth about $2,984,000. 25.73% of the stock is currently owned by hedge funds and other institutional investors.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.